Wall St. darling Penumbra launches latest thrombectomy device in the U.S.

Penumbra's ACE 68 Reperfusion Catheter

Penumbra ($PEN), one of the top devicemaker IPOs last year, unveiled its latest thrombectomy product to the U.S. market.

Dubbed the ACE 68 Reperfusion Catheter, the vascular device uses the latest tracking technology to extract blood clots in acute ischemic stroke patients more quickly and safely, the company said. The device, which is part of the company’s Penumbra System, was designed with a new tracking platform from hub to tip, and features a unique coil winding geometry along 16 transitions to deliver an optimal tracking profile.

The announcement, along with supporting data, was made Monday at the Society of NeuroInterventional Surgery’s 13th Annual Meeting in Boston.

“The ACE68 provides an opportunity to reverse strokes faster and with less expense,” Dr. Adam Arthur, a professor in the neurosurgery department at the Semmes-Murphey Neurologic & Spine Institute in Memphis, TN, said in a statement. “The larger lumen seems to allow better clot capture, which may reduce the need for adjunctive devices, simplify the procedure and reduce procedure cost-- important considerations as hospitals look to expand stroke services.”

The Alameda, CA-based company markets medical devices that include several neurovascular access products, the ACE system, neurovascular embolization products, a neurosurgical tool as well as peripheral embolization and thrombectomy devices.

Penumbra, which raised about $125 million when it went public last September, has seen its stock price trade in a 52-week range of $35.31 to $61.87. Canaccord Genuity, which recently set a price target of $67 per share for Penumbra, has raised its rating of the company to a buy. Canaccord pegged Penumbra’s market cap at $1.83 billion with a price-to-earnings ratio of 959.19.

Zacks Investment Research also recently raised Penumbra from a hold rating to buy and set a $68 price target. 

In May, Penumbra reported total revenue grew to $57.9 million in Q1 versus $39 million for the same period a year ago. Analysts had set a consensus estimate of $53.1 million. Revenue for neuro products grew to $41.3 million for the period, and sales of peripheral vascular products increased to $16.6 million.

- check out the release

Related Articles:
Profitable neuro, vascular device player Penumbra files for up to $115M IPO
Med tech IPOs fall into place: Penumbra, Symetis, Novocure and Adesto

Read more on